Skip to Main Content

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Conditions

Anus | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Stomach | Thyroid | Unknown Sites | Breast | Urinary Bladder

Phase II

What is the purpose of this trial?

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

  • Trial with
    Southwest Oncology Group (SWOG)
  • Start Date
    11/19/2017
  • End Date
    08/30/2020

For more information about this study, contact:

Matthew Piscatelli

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/04/2018
  • Study HIC
    #2000020739